While, selective COX-2 inhibitors have been shown to increase sensitivity of cancer cells to chemotherapy via reduction of drug resistance in human patients with AML, breast, ovarian and colon cancer (3, 19, 22, 23). This evidence concerns the gene PTGS2 and malignant colon neoplasm.